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Abstract
Introduction: Gout is a common arthritis that occurs particularly in patients who frequently have associated
comorbidities that limit the use of conventional therapies. The main mechanism of crystal-induced inflammation is
interleukin-1 production by activation of the inflammasome. We aimed to evaluate the efficacy and tolerance of
anakinra in gouty patients.
Methods: We conducted a multicenter retrospective review of patients receiving anakinra for gouty arthritis. We
reviewed the response to treatment, adverse events and relapses.
Results: We examined data for 40 gouty patients (32 men; mean age 60.0 ± 13.9 years) receiving anakinra. Mean
disease duration was 8.7 ± 8.7 years. All patients showed contraindications to and/or failure of at least two
conventional therapies. Most (36; 90%) demonstrated good response to anakinra. Median pain on a 100-mm visual
analog scale was rapidly decreased (73.5 (70.0 to 80.0) to 25.0 (20.0 to 32.5) mm, P <0.0001), as was median C-
reactive protein (CRP) level (130.5 (55.8 to 238.8) to 16.0 (5.0 to 29.5) mg/l, P <0.0001). After a median follow-up of
7.0 (2.0 to 13.0) months, relapse occurred in 13 patients after a median delay of 15.0 (10.0 to 70.0) days. Seven
infectious events, mainly with long-term use of anakinra, were noted.
Conclusions: Anakinra may be efficient in gouty arthritis, is relatively well tolerated with short-term use, and could
be a relevant option in managing gouty arthritis when conventional therapies are ineffective or contraindicated. Its
long-term use could be limited by infectious complications.
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Introduction
Gout is a common arthritis caused by deposition of
monosodium urate (MSU) crystals within and around
joints secondary to chronic hyperuricemia. It affects 1%
to 2% of adults in developed countries and may be
increasing in prevalence [1]. Acute gouty arthritis may
be associated with high inflammatory clinical and biolo-
gical symptoms. Thus, one of the goals of management
is rapid relief of inflammation [2,3].
Acute gouty attacks are usually treated with nonsteroi-
dal anti-inflammatory drugs (NSAIDs), colchicine and
corticosteroids [3]. Gouty patients often have concomi-
tant renal, cardiovascular and gastrointestinal diseases as
well as diabetes mellitus [4]. These comorbidities and
associated treatments can lead to increased frequency of
side effects or contraindications to conventional thera-
pies for gouty arthritis [4]. We have abundant evidence
of side effects from the use of colchicine (for example,
for diarrhea) [5] and NSAIDs (for example, for gastroin-
testinal bleeding, cardiovascular events including myo-
cardial infarction, renal impairment) [6,7], so care must
be taken when prescribing such drugs. Thus, alternative
therapies are needed for these ‘difficult-to-treat’ cases.
The main mechanism of crystal-induced inflammation is
interleukin 1b (IL-1b) production by activation of the
NLRP3 inflammasome [8], which strengthens the rele-
vance of targeting IL-1b in patients with crystal-induced
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arthritis. Anti-IL-1 agents, such as anakinra, have been
evaluated in gouty arthritis, for treating acute attacks or
for preventing gouty attacks while initiating urate-lowering
therapy [9-14]. To date, only two small open studies have
evaluated the efficacy of anakinra in acute gouty arthritis
[13,14] although anakinra has been labeled for rheumatoid
arthritis treatment for more than 10 years. Other IL-1
inhibitors, canakinumab and rilonacept, appear to be effec-
tive in reducing pain and signs of inflammation in rando-
mized controlled trials, which validate IL-1 as playing a
pivotal role in gout inflammation [9,10,12,15].
Here, we aimed to evaluate the efficacy and safety of
anakinra in patients with acute and chronic gouty arthritis




This was a multicenter retrospective review of charts for
patients who received anakinra for gouty arthritis.
Patients were identified by treating rheumatologists and
by searching available electronic medical records with the
keyword ‘anakinra’ or ‘Kineret®’. Patients receiving ana-
kinra who had concomitant connective tissue diseases
were not included. Inclusion criteria were diagnosis of
gouty arthritis defined as recommended by the identifica-
tion of MSU crystals in synovial fluid [16] and at least
one documented visit after the acute gouty arthritis
requiring anakinra. The study was approved by the
local institutional review board of Paris North Hospitals
(No. 12-081) and all patients provided informed written
consent to their physician to receive anakinra.
Evaluation
We retrospectively assessed response to anakinra at base-
line and at the first documented visit following the acute
gouty arthritis according to the following items: swollen
joint count (SJC) and tender joint count (TJC), patient
evaluation of pain by a visual analog scale (VAS pain, 0
to 100 mm) and C-reactive protein (CRP) levels (mg/L).
We collected data on demographics (age, gender), clinical
variables (tophus, localization of arthritis, comorbid con-
ditions, and disease and flare duration), radiologic fea-
tures of gouty arthropathy and biological variables
(serum uric acid levels (SUA), CRP and creatinine). The
outcome of anakinra treatment was classified as good,
partial, or no response. A good response was arbitrarily
defined as an improvement >50% in VAS pain or CRP
level and/or documentation in the chart of the word
‘good’ response after anakinra treatment. A partial
response was defined as a report of improvement in joint
symptoms but not a ‘good’ response (20% to 50%
improvement). No response was defined as the absence
of symptom relief (<20% improvement).
Adverse events were defined as diarrhea, myopathy and
skin reactions with colchicine treatment; gastrointestinal
bleeding, cardiovascular events, renal impairment and
skin reactions with NSAIDs; hyperglycemia, hypertension
and cardiovascular events with steroids; and local skin
reaction, infection and neutropenia with anakinra.
Contraindications to conventional therapies and
comorbidities were as described [4], except for osteo-
porosis and hyperlipidemia, which we did not consider a
comorbidity limiting prescription of conventional
therapies.
Statistical analysis
Data are reported as mean ± SD or median (interquartile
range (IQR)) or number (%). Non-parametric or Fisher’s
exact test was used to compare quantitative or categorical




We investigated data for 40 patients (32 men) who
received anakinra for gouty arthritis. Their baseline char-
acteristics are shown in Table 1. In all, 79% and 92% of
patients showed clinical tophi and gouty arthropathy,
respectively.
At baseline, the median (IQR) pain level was 73.5 (70.0 to
80.0) mm. The median TJC and SJC was 5.0 (3.5 to 8.0)
and 4.0 (3.0 to 5.5), respectively. The median CRP level
was 130.5 (55.8 to 238.8) mg/L. The mean SUA was 534 ±
172 μM. In all, 17 (43%) patients had received urate-
lowering therapy (allopurinol (n = 11), febuxostat (n = 6),
benzbromarone (n = 1)). Diuretic drugs were prescribed
for 14 patients (hydrochlorothiazides (n = 3), loop diure-
tics (n = 11)). All patients had a contraindication to or
past history of adverse events with conventional treat-
ments for acute gouty arthritis (Table 1).
The number of patients with gouty arthritis that was
acute (<6 weeks), subacute (6 to 12 weeks) and chronic
(>12 weeks) was 34, 2 and 4, respectively.
Among the 40 patients, 23 received anakinra following
the protocol used by So et al.[14]: 100 mg daily for three
days subcutaneously. Seven patients received anakinra for
<15 days (100 mg/day: n = 6, 100 mg/2 days: n = 1). The
10 remaining patients received anakinra for the long
term (>15 days), followed by a spacing of the dose regi-
men (median total duration: 5.0 (2.3 to 11.8) months).
Anakinra response for gouty arthritis
Whole population
Of the 40 patients, good, partial and non-response to ana-
kinra were noted in 36 (90%), 2 (5%) and 2 patients (5%),
respectively. Pain score decreased from 73.5 (70.0 to 80.0)
to 25.0 (20.0 to 32.5) mm, P <0.0001), as did CRP
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level (130.5 (55.8 to 238.8) to 16.0 (5.0 to 29.5) mg/L,
P <0.0001) (Figure 1). In all, 30 patients received treatment
to prevent relapse (Table 2). After a median follow-up of
7.0 (2.0 to 13.0) months, relapse occurred in 13 (32.5%)
patients with a median delay of 15.0 (10.0 to 70.0) days.
Relapse occurred particularly in patients not receiving
therapy to prevent acute flare (7/10 versus 6/30, P =
0.006). No relapse occurred with long-term use of ana-
kinra (>15 days).
Anakinra response according to the dose regimen
A total of 23 patients received anakinra, 100 mg/day, for
up to three days, with good response in 20 (87%); 17 (74%)
showed relapse prevention after resolution of the flare.
After a median follow-up of 6.0 (1.5 to 14.0) months,
relapse occurred in six (26%) patients at a median delay of
15.0 (6.0 to 26.3) days.
In all, 17 patients received anakinra for more than three
days, with good response in 16 (94%); 13 (76%) showed
Table 1 Baseline characteristics of patients receiving anakinra for gouty arthritis.
Baseline characteristics Clinical characteristics of gouty patients
Number of patients 40
Number of men (%) 32 (80%)
Comorbid conditions (number; %) HT (27; 68%), CKD 3-5 (22; 55%), CAD (17; 43%), AI (13; 33%), DM (9; 23%), GU (6; 15%),
transplant (2 (kidney, heart); 5%), asthma (1; 3%),
Associated therapies (number; %) LDA (8; 20%), oral anticoagulant (3; 8%),
Age, year, mean ± SD 60.0 ± 13.9
Disease duration, year, mean ± SD 8.7 ± 8.7
Flare duration, number patients (days, mean ± SD)
Acute (<6 weeks) 34 (9.4 ± 8.1)
Subacute (6 to12 weeks) 2 (60.0 ± 1.4)
Chronic (>12 weeks) 4 (130 ± 45.8)
Localization of arthritis, (number; %) Knees (30; 75%), wrists (22; 55%), ankles (24; 60%), MTP1s (20; 50%), MCPs (12; 30%), elbows
(12; 30%), tarsae (6; 15%), shoulders (2; 5%)
Reason for anakinra use
Non-response to conventional therapies,
(number; %)
Colchicine (24; 60%), NSAIDs (11; 27.5%), steroids (7; 17.5%)
Adverse events or contraindication to
conventional therapies, (number; %)
Colchicine (16; 40%), NSAIDs (29; 72.5%), steroids (9; 22.5%)
AI, alcohol intake; CAD, coronary heart disease; CKD, chronic kidney disease; DM, diabetes mellitus; GU, gastric ulcer; HT, hypertension, LDA, low-dose aspirin;
MCPs, metacarpophalangeal joints; MTPs, metatarsophalangeal joints; NSAIDs, non-steroidal anti-inflammatory drugs.
Figure 1 Pain on a visual analog scale (VAS) and C-reactive protein level (CRP) on days 1 and 4 of anakinra treatment for gouty
arthritis. VAS, visual analog scale (mm); CRP, C-reactive protein (mg/l).
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relapse prevention after flare resolution. After a median
follow-up of 8.0 (3.0 to 13.0) months, relapse occurred in
seven (41%) patients at a median delay of 60.0 (12.5 to
125.0) days.
Tolerance
No patient reported anakinra-related skin hypersensitiv-
ity. A total of seven infectious complications, mainly sta-
phylococcal infections, were reported in six patients
(Table 2). One H1N1 viral infection occurred one day
after anakinra was started (previously reported in [17]).
All other infectious complications occurred in patients
with long-term use of anakinra and were successfully
treated with antibiotics. Of the six patients, five restarted
anakinra after the resolution of infection. No patient has
shown tuberculosis or pneumococcal infection.
Discussion
Recently, the emerging role of IL-1b in the pathogenesis of
inflammation in crystal-induced arthritis [8,18,19] led to
considering anti-IL-1 therapies as a relevant alternative to
conventional therapies for gouty arthritis. Here, we report
on our experience with anakinra therapy, a recombinant
receptor antagonist against IL-R blocking both IL-1b and
b, for gouty arthritis in a large series of patients. Our
results are in good agreement with those of the first open-
label trial of anakinra showing improved patient-reported
symptoms by at least 50% of all 10 patients enrolled [14].
Chen et al. suggested an efficiency in 6 of 10 patients with
good response [13]. Similar to So et al., we observed a
rapid decrease of both VAS pain and CRP levels. Recently,
randomized controlled trials found that two anti-IL-1b
biologic agents (rilonacept and canakinumab) prevented
gouty arthritis during the initiation of urate-lowering
therapy with allopurinol [10,11], but only canakinumab
demonstrated efficacy for acute gouty arthritis [9,12].
In these cases, rilonacept failed to induce a rapid relief of
symptoms [20] but could decrease pain in chronic gouty
arthritis [15]. These data strengthen the argument to target
IL-1 blockade for acute gouty arthritis. Of interest, canaki-
numab recently obtained European authorization [21].
In our study, relapse occurred frequently among patients
not receiving therapy to prevent acute flare, and conversely,
no patient with long-term use of anakinra experienced
relapse. The daily subcutaneous injection could limit the
use of the drug in preventing flare, although skin tolerance
was excellent in our study. The short-term regimen was
well tolerated: only one viral infection was observed. This
short-term good tolerance agrees with previous studies of
anakinra for gouty arthritis [13,14] and pseudogout [22,23].
However, long-term use was poorly tolerated, with six
infectious events, notably one septic arthritis and one
patient with pulmonary abscesses. These data suggest a
risk of infection with prolonged administration. To date,
the role IL-1 antagonists could play in clinical practice is
unclear. Nonetheless, their cost (38€ per injection in
France, 2013) may not be excessive in managing acute
attacks, particularly in patients with contraindications to,
or who cannot tolerate, conventional therapies. Recently,
American College of Rheumatology recommendations
Table 2 Response and follow-up of gouty arthritis patients receiving anakinra.
Follow-up characteristics Anakinra for ≤3 days
Number = 23
Anakinra for >3 days
Number = 17
Response to anakinra, number (%)
Good 20 (87%) 16 (94%)
Partial 2 (9%) 0 (0%)
No response 1 (4%) 1 (6%)
Follow-up duration, months, median (IQR) 6.0 (1.5 to 14.0) 8.0 (3.0 to 13.0)
Prevention of relapse, number (%)
Total 17 (74%)a 13 (76%)
Low-dose colchicine 16 (89%) 7 (54%)
NSAIDs 3 (17%) 1 (8%)
Steroids 1 (6%) 2 (15%)
Anakinra 1 (6%) 9 (69%)
Relapse, number (%) 6 (26%) 7 (41%)
Delay to relapse, days, median (IQR) 15.0 (6.0 to 26.3) 60.0 (12.5 to 125.0)
Skin reaction None None
Infectious events under anakinra therapy
(delay after starting anakinra)
H1N1 infection (1 day) Staphylococcus aureus tophus (1 year)
S. aureus tophus (4 years)
S. aureus lung abcess (1 month)
Erysipela of the leg (2 months)
Streptococcus B urinary tract infection (1 month)
S. aureus knee arthritis (1 year)
aSome patients also had different treatment. IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs.
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allow for use of anti-IL1 agents when conventional thera-
pies have failed or are contraindicated [2]. Of note, ana-
kinra, with the shortest half-life of the IL-1 blockers, could
be a relevant option to manage acute gouty arthritis.
Our study had some limitations. First, data were retro-
spectively collected, with varied use of anakinra, and we
had no control group. However, this real-life observational
study is the largest reported series for this treatment.
Randomized controlled studies are necessary to clarify
the place of anakinra in the management of gouty
arthritis flare.
Conclusions
Our results provide evidence that anakinra is effective,
relatively well tolerated with short-term use, and could
be a good alternative for treating gouty arthritis in
patients for whom conventional therapies are ineffective
or contraindicated. Although these findings are promis-
ing, this was a retrospective study, and future randomized
controlled trials are required definitely to determine the
place of anakinra in managing gouty arthritis.
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